FDA Extends PDUFA Date for VIVUS's (VVUS) Qnexa NDA to July 17th
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Trade VVUS Now!
The U.S. FDA informed VIVUS (Nasdaq: VVUS) of an extended Prescription Drug User Fee Act (PDUFA) date for its review of the Qnexa New Drug Application (NDA) from April 17 to July 17, 2012. The three-month extension is a standard extension period.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- VIVUS, Inc. (VVUS) to Make Several Scientific Presentations in May
- J. C. Penney (JCP) Enters $2.25B Secured Term Loan Facility
- Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
